<DOC>
	<DOCNO>NCT00248339</DOCNO>
	<brief_summary>The purpose study determine use epoetin-alpha allow patient chronic hepatitis C virus infection treat high dos peginterferon-alpha-2b ribavirin , thus increase chance low viral level raise sustain virologic response .</brief_summary>
	<brief_title>Trial Peg-interferon Plus Epoetin-alfa Treatment Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>Chronic infection hepatitis C virus ( HCV ) lead cirrhosis , hepatocellular carcinoma liver failure . The treatment end stage liver disease hepatic transplantation . It therefore important patient chronic HCV infection recognize treat develop advanced disease . The effective therapy patient chronic HCV appear combination peginterferon-alpha-2b ( PEG-Intron ) plus ribavirin . Overall , 54 % patient treated medication achieve sustain virologic response . Response therapy greatly enhance patient tolerate therapy remain treatment without need dose reduction . The single common reason reduce dose ribavirin anemia . Ribavirin cause dose dependent hemolytic anemia side effect believe exacerbated marrow suppressive effect interferon . Preliminary study suggest anemia overcome use erythropoetin . The present pilot study test hypothesis treatment Epoetin-alph allow patient chronic HCV utilize high dos ribavirin along PEG-Intron therapy lead rapid decline HCV RNA titer increase sustain virologic response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>HCV RNA positive serum HCV genotype 1 Liver histology consistent chronic HCV perform within 24 month prior start medication study Previous interferon treatment Any cause liver disease Hemoglobin &gt; 10 gm/dl WBC &gt; 3,000/cubic mm Platelet count &gt; 80,000/cubic mm Serum albumin &lt; 3.5 gm.dl Conjugated serum bilirubin &gt; 2.0 mg/dl INR &gt; 1.5 Positive HIV test Refusal use adequate contraception female subject spouse.sexual partner male subject An elevation TSH ( thyroid stimulate hormone ) . Patients preexist thyroid disorder may enter study TSH level maintain within normal range . Women pregnant breast feeding . A history decompensated liver disease define presence ascites , bleed esophageal gastric varix hepatic encephalopathy . Patients active alcohol/drug use . Patients active psychiatric disorder might exacerbate interferon therapy include schizophrenia severe depression . Use immune suppressive medication within 3 month start interferon therapy . A history cardiac disease include recent myocardial infarction angina . Patients previous exposure Procrit , Aranesp , GA_EPO , Epoetin formulation , within 6 month prior enrollment study . Patients know sensitivity mammalian cellderived product . Patients know hypersensitivity human albumin . Patients unable provide inform consent . Any medical condition primary investigator feel might exacerbate jeopardise patient 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Peginterferon</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Procrit</keyword>
	<keyword>Epoetin-alpha</keyword>
</DOC>